Three-dimensional imaging of hormone-secreting cells and their microvessel environment in estrogen-induced prolactinoma of the rat pituitary gland by confocal laser scanning microscopy.
This study focused on the three-dimensional imaging of hormone-secreting cells and their microvascular environment in estrogen-induced prolactinoma of the rat pituitary gland. Adult female Wistar-Imamichi rats were injected with estradiol dipropionate and killed 7 weeks later. Some rats given estrogen for 7 weeks also were injected with bromocriptine before killing. To obtain a detailed three-dimensional image of microvessels, dialyzed fluorescein isothiocyanate (FITC)-conjugated gelatin was injected into the left ventricle of the rat heart. After the perfusion, the pituitary glands were resected and subjected to immunohistochemistry (IHC). To evaluate the effects of estrogen and bromocriptine, IHC was performed with antibodies against prolactin (PRL), adrenocorticotropic hormone (ACTH), and growth hormone (GH). With the combination, microvessels and cells containing PRL, ACTH, and GH could be clearly identified by confocal laser scanning microscopy (CLSM). The PRL cells increased in number and became hypertrophic after prolonged exposure to estrogen. With bromocriptine administration after estrogen treatment, however, PRL cells decreased in number and became atrophic. The current study revealed that estrogen and bromocriptine had significant effects on PRL secretion and the microvascular environment. Therefore, this technique (FITC injection and IHC) with CLSM is suitable for the three-dimensional imaging of hormone-secreting mechanisms under various conditions.
Itoh
J
J
Laboratories for Structure and Function Research, Tokai University, School of Medicine, Isehara, Kanagawa, Japan. itohj@is.icc.u-tokai.ac.jp
Kawai
K
K
Serizawa
A
A
Yamamoto
Y
Y
Ogawa
K
K
Matsuno
A
A
Watanabe
K
K
Osamura
R Y
RY
D000324:Adrenocorticotropic Hormone / Q000032:analysis; D000818:Animals; D001971:Bromocriptine / Q000008:administration & dosage / Q000494:pharmacology; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D004967:Estrogens / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D013006:Growth Hormone / Q000032:analysis; D006727:Hormone Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D021621:Imaging, Three-Dimensional; D007150:Immunohistochemistry; D008833:Microcirculation / Q000166:cytology / Q000187:drug effects; D018613:Microscopy, Confocal; D010902:Pituitary Gland / Q000166:cytology / Q000187:drug effects; D010911:Pituitary Neoplasms / Q000098:blood supply / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology*; D011388:Prolactin / Q000032:analysis; D015175:Prolactinoma / Q000098:blood supply / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology*; D051381:Rats; D017208:Rats, Wistar
D004967:Estrogens; D006727:Hormone Antagonists; D001971:Bromocriptine; D004958:Estradiol; D000324:Adrenocorticotropic Hormone; D011388:Prolactin; D013006:Growth Hormone; C023482:estradiol dipropionate